Bank of America began coverage on shares of Prevail Therapeutics (NASDAQ:PRVL) in a research note released on Monday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $15.00 price objective on the stock.

Separately, Cowen reissued a buy rating on shares of Avrobio in a research note on Monday.

Shares of NASDAQ:PRVL opened at $12.10 on Monday. Prevail Therapeutics has a 12 month low of $9.83 and a 12 month high of $16.90.

In other news, Director Carl L. Gordon purchased 882,352 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were acquired at an average price of $17.00 per share, with a total value of $14,999,984.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Prevail Therapeutics Company Profile

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Featured Article: What is the Gross Domestic Product (GDP)?

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with's FREE daily email newsletter.